| Synthesis, spectroscopic, and photophysical characterization and photosensitizing activity toward prokaryotic and eukaryotic cells of porphyrin-magainin and-buforin conjugates R Dosselli, R Ruiz-Gonzalez, F Moret, V Agnolon, C Compagnin, ... Journal of medicinal chemistry 57 (4), 1403-1415, 2014 | 66 | 2014 |
| Trimeric SARS-CoV-2 spike proteins produced from CHO cells in bioreactors are high-quality antigens P Pino, J Kint, D Kiseljak, V Agnolon, G Corradin, AV Kajava, P Rovero, ... Processes 8 (12), 1539, 2020 | 22 | 2020 |
| ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with … V Agnolon, A Contato, A Meneghello, E Tagliabue, G Toffoli, M Gion, ... Scientific Reports 10 (1), 3016, 2020 | 20 | 2020 |
| The potential of adjuvants to improve immune responses against TdaP vaccines: a preclinical evaluation of MF59 and monophosphoryl lipid A V Agnolon, C Bruno, R Leuzzi, B Galletti, U D’Oro, M Pizza, A Seubert, ... International Journal of Pharmaceutics 492 (1-2), 169-176, 2015 | 18 | 2015 |
| Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines V Agnolon, C Bruno, B Galletti, E Mori, M Ugozzoli, C Pergola, ... Vaccine 34 (8), 1040-1046, 2016 | 17 | 2016 |
| The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine C Bruno, V Agnolon, F Berti, S Bufali, DT O’Hagan, BC Baudner European Journal of Pharmaceutics and Biopharmaceutics 105, 1-8, 2016 | 16 | 2016 |
| Designs and characterization of subunit Ebola GP vaccine candidates: implications for immunogenicity V Agnolon, D Kiseljak, MJ Wurm, FM Wurm, C Foissard, F Gallais, ... Frontiers in immunology 11, 586595, 2020 | 9 | 2020 |
| Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels ASC Fabricio, S Michilin, M Zancan, V Agnolon, L Peloso, R Dittadi, ... Scandinavian Journal of Clinical and Laboratory Investigation 79 (4), 260-267, 2019 | 7 | 2019 |
| P. falciparum and P. vivax Orthologous Coiled-Coil Candidates for a Potential Cross-Protective Vaccine I Ayadi, S Balam, R Audran, JP Bikorimana, I Nebie, M Diakité, I Felger, ... Frontiers in immunology 11, 574330, 2020 | 4 | 2020 |
| Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with sera from Plasmodium falciparum endemic areas of Africa M Arévalo-Herrera, S Balam, K Miura, I Ayadi, D Konaté, NC Incandela, ... bioRxiv, 2024.04. 10.588966, 2024 | | 2024 |
| Ebola vaccine compositions and methods of using same D Kiseljak, FM Wurm, V Agnolon, F Spertini, B Correia US Patent App. 17/271,657, 2021 | | 2021 |
| Trimeric SARS-CoV-2 Spike proteins produced from CHO-cells in bioreactors are high-quality antigens (preprint) P Pino, D Kiseljak, V Agnolon, G Corradin, AV KAJAVA, P Rovero, ... | | 2020 |
| Design and characterization of near-native Ebola GP vaccine candidates: implications for immunogenicity V Agnolon, I Ayadi, JP Bikorimana, D Kiseljak, V De Vaux, S Wehrle, ... Swiss Medical Weekly 148, 6S-7S, 2018 | | 2018 |
| COMPARISON BETWEEN OVARIAN MALIGNANCY ALGORITHM (ROMA) AND IOTA RISK MODEL (LR2) FOR DIFFERENTIAL DIAGNOSIS OF ADNEXAL MASSES: REAL-WORLD STUDY C Romagnolo, ASC Fabricio, AE Leon, M Taborelli, V Agnolon, ... INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 27, 421-421, 2017 | | 2017 |
| A formulation science perspective applied to combination vaccines: particles-based multiplex immunoassays for improved antigens characterization and rational design of … V Agnolon Università degli studi di Padova, 2015 | | 2015 |
